Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
MindMaze Therapeutics Holding SA develops and commercializes precision digital treatments for neurological diseases and brain disorders. Its brain technology platform integrates software, proprietary sensors, telehealth, and AI-driven data analytics to support care from acute hospital treatment to outpatient and home-based therapy.
Company news covers FDA-cleared and CE-marked neurotherapeutics for areas such as stroke and Parkinson's disease, reimbursement strategy across healthcare systems, clinical validation, and R&D expansion into adjacent neurological indications. Updates also include the completed business combination that formed the MindMaze Therapeutics identity, along with shareholder voting, governance, capital-structure, and financial-reporting matters.
Relief Therapeutics Holding AG (OTCQB: RLFTF) has addressed disputes with partner NeuroRx, Inc. regarding the collaboration on RLF-100 (aviptadil). Key issues include NeuroRx's refusal to share clinical trial data, a claim of $4 million in unpaid invoices without valid documentation, and disputes over funding responsibilities for a new clinical trial for COVID-19 treatment. Relief believes these points may affect profit-sharing agreements outlined in their collaboration. Despite these challenges, Relief plans to take necessary actions to enforce its rights under the collaboration agreement.
Relief Therapeutics reported its 2020 financial results on April 15, 2021, highlighting a strong cash position of CHF 43.1 million, up from CHF 0.1 million in 2019. Key developments included advancement in the clinical trials for RLF-100 (aviptadil) for COVID-19 and a new collaboration for ACER-001 targeting orphan diseases. Despite a significant EBITDA loss of CHF 20.3 million, the company successfully raised CHF 58 million in equity financing throughout 2020. Looking ahead, Relief plans to expand its pipeline and pursue regulatory submissions for its lead projects.
Relief Therapeutics Holding AG has appointed J.J. Scherpbier as Manufacturing and Supply Chain Consultant, effective April 1, 2021. Mr. Scherpbier, with over 25 years of experience in pharmaceutical development, will focus on establishing a supply chain for ACER-001, a drug for Urea Cycle Disorders. The company aims to diversify its portfolio and enhance its development capabilities, particularly for RLF-100 (aviptadil), which is in late-stage testing for COVID-19 related respiratory issues. Relief is listed on the SIX Swiss Exchange (RLF) and OTCQB (RLFTF).
NeuroRx reported promising outcomes from its Phase 2b/3 trial of ZYESAMI™ (aviptadil acetate) for COVID-19-induced respiratory failure. The trial, involving 196 patients across 10 sites, met its primary endpoints at 28 days (P = .014) and 60 days (P = .013). Notably, patients treated with ZYESAMI™ had a 75% recovery rate by day 60, outperforming 55% in the placebo group (P = .036). The drug also significantly increased survival rates, particularly among patients receiving High Flow Nasal Cannula (P = .007). NeuroRx plans to submit an EUA application to the FDA and expand its trials further.
Relief Therapeutics Holding AG announces progress on its lead compound RLF-100(TM) (aviptadil) in collaboration with NeuroRx, Inc. They are evaluating the feasibility of formulating RLF-100(TM) as a dry powder using Thin-Film Freezing (TFF) technology. This method may enhance drug delivery, allowing up to 75% deposition in the lungs and eliminating cold chain shipping. The company is focused on advancing treatments for respiratory diseases, particularly related to COVID-19, with ongoing late-stage clinical trials. Relief holds a U.S. patent for RLF-100(TM).
Relief Therapeutics (OTCQB: RLFTF) has announced a private placement agreement to sell 41,459,370 shares at CHF 0.2412 each, aiming to raise approximately CHF 10 million. The offering is set to close around March 16, 2021, pending customary conditions. Proceeds will be used to enrich the drug pipeline and for corporate purposes. CFO Jack Weinstein highlighted this financing as a crucial step to broaden their pipeline, particularly in relation to RLF-100, a candidate for COVID-19 treatment undergoing late-stage trials.
Relief Therapeutics has increased its registered share capital from 3,246,727,248 to 3,371,727,248 shares, issuing 125,000,000 new shares at CHF 0.01 each. These shares, subscribed by Relief Therapeutics International SA, will be listed on the SIX Swiss Exchange around March 11, 2021, allowing for greater financial flexibility. The company is focused on developing RLF-100TM (aviptadil) for severe COVID-19 cases, currently in late-stage clinical trials.
Relief Therapeutics announced updates on its lead compound RLF-100(TM) (aviptadil), which is in advanced clinical trials for treating respiratory failure in critical COVID-19 patients. Data from a Phase 2b/3 trial, managed by NeuroRx, indicates that RLF-100(TM) has shown promising results, significantly accelerating patient recovery. The company holds various patents for the drug and focuses on clinical-stage programs for respiratory diseases. It is publicly traded under the symbols RLF in Switzerland and RLFTF in the U.S.
NeuroRx announced positive interim results for ZYESAMI™ (aviptadil) in a Phase 2b/3 trial for treating respiratory failure in critically ill Covid-19 patients. The drug showed a 35% higher likelihood of recovery by day 28 compared to placebo, with a median 10-day acceleration in recovery time. As High Flow Nasal Oxygen becomes the main treatment for such patients, NeuroRx plans to apply for Emergency Use Authorization if positive trends continue. The trial involved 10 U.S. hospitals and is part of a collaboration with RELIEF THERAPEUTICS. NeuroRx is also completing a business combination with Big Rock Partners Acquisition Corporation (BRPA).
On February 9, 2021, NeuroRx and Relief Therapeutics announced preliminary results from the Phase 2b/3 trial of ZYESAMI™ in COVID-19 patients experiencing respiratory failure. The trial indicated significant improvements for patients receiving ZYESAMI compared to those on placebo, including earlier hospital discharge and reduced ICU time. The data suggests a potential Emergency Use Authorization submission for ZYESAMI, indicating its importance as the first drug specifically targeting critically ill COVID-19 patients. However, primary endpoint results are still pending.